Views 151
Citations 0
Comment & Response
July 2016

Confirmatory Testing for Onychomycosis

Author Affiliations
  • 1Department of Dermatology, University of Alabama at Birmingham School of Medicine, Birmingham

Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA Dermatol. 2016;152(7):848. doi:10.1001/jamadermatol.2016.0786

To the Editor Mikailov and colleagues1 propose that the empirical treatment of onychomycosis with terbinafine without confirmatory testing is cost-effective. While the approach may be reasonable when disease prevalence is exceedingly high, prescribing medications with known adverse effects, some serious, leads to delay in correct treatment and unnecessary therapy for patients with dystrophic nails who do not have onychomycosis. In fact, only about half of dystrophic nails are caused by fungi2,3; the other half are manifestations of psoriasis, lichen planus, and trauma, among other causes. If empirical treatment is provided for clinically suspected onychomycosis in dystrophic nails, correct treatment is delivered only half the time, the same probability as a random coin flip. The calculations of cost savings using 75% disease prevalence by Mikailov et al1 overestimate savings. Fingernail dystrophy without toenail involvement is seldom caused by a dermatophyte; therefore, empirical treatment with terbinafine should be administered with caution. Furthermore, recent meta-analyses for the prevalence of onychomycosis in Europe and North America estimate it to be only 4%, with previous reports of 7% to 14% in North America.35

First Page Preview View Large
First page PDF preview
First page PDF preview